RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00127582
Recruitment Status : Unknown
Verified May 2005 by Catholic University of the Sacred Heart.
Recruitment status was:  Recruiting
First Posted : August 8, 2005
Last Update Posted : August 25, 2005
Fondazione Telethon
Information provided by:
Catholic University of the Sacred Heart

August 4, 2005
August 8, 2005
August 25, 2005
January 2003
Not Provided
  • Evaluate incidence of: major cardiac events (sudden death
  • resuscitated cardiac arrest
  • ventricular fibrillation
  • sustained ventricular tachycardia
  • sinoatrial and atrioventricular [AV] blocks)
  • Evaluate incidence of:
  • 1) major cardiac events (sudden death, resuscitated cardiac arrest, ventricular fibrillation, sustained ventricular tachycardia, sinoatrial and AV blocks).
Complete list of historical versions of study NCT00127582 on Archive Site
  • Evaluate with diagnostic non-invasive (standard electrocardiogram [ECG]
  • 24-hour monitoring ECG
  • signal-averaged ECG
  • echocardiography) and invasive procedures (electrophysiology study [EPS] and implantable loop recorders) the risk to develop cardiac arrhythmias in DM patients
Evaluate with diagnostic non-invasive (standard ECG, 24-hour monitoring ECG, signal-averaged ECG, echocardiography) and invasive procedures (EPS and implantable loop recorders) the risk to develop cardiac arrhythmias in DM patients.
Not Provided
Not Provided
RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1)
This is a prospective multicentric Italian study to evaluate the arrhythmic risk in myotonic dystrophy type 1.

Myotonic dystrophy type 1 (DM1, Steinert disease) is a multisystem disorder that affects, beside muscle, several other organs, including the heart.

Cardiac involvement represents a major problem in the clinical management of patients, so that cardiac complications represent one of the primary causes of premature death in DM1. In particular there is a high incidence of sudden death, ranging from 2 to 30% of cases, so far principally related to the development of conduction blocks. However, literature reports of sudden death in patients implanted with pacemakers, as well as of spontaneous ventricular tachycardia would suggest a potential etiologic role also for ventricular arrhythmias. The lack of clinical research studies conducted on a large number of patients does not make available definite data regarding the etiology and the epidemiology of arrhythmic events in DM1. For the same reasons, other considerable topics, such as prognostic stratification of the arrhythmic risk and clinical management of life-threatening arrhythmias in DM1 patients, are still undefined.

To clarify these issues, the investigators propose a clinical research study performed on a large cohort of DM1 patients enrolled through a multicenter collaboration that also involves 5 cardiological-neurological Italian centres.

Aims of this study are:

  • To estimate the incidence of arrhythmias and to characterize the brady-tachyarrhythmic mechanisms underlying the occurrence of cardiac sudden death in DM1;
  • To verify by statistical analysis the reliability of data obtained from both non invasive and invasive diagnostic procedures as indexes useful for estimating the arrhythmic risk in DM1;
  • To identify more adequate therapeutic guidelines in order to prevent the occurrence of life-threatening arrhythmias.

The protocol of study includes:

  1. Clinical-genetic evaluation;
  2. Non invasive and invasive diagnostic cardiac procedures;
  3. The use of devices for diagnostic and therapeutic follow-up.
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Myotonic Dystrophy
  • Sudden Cardiac Death
  • Procedure: Electrophysiological study
  • Device: pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
Not Provided
Not Provided

Inclusion Criteria:

  • Patient affected by myotonic dystrophy type I (MD1).
  • Patient willing to provide a signed informed consent.

Exclusion Criteria:

  • Age < 18 years old or >70 years old.
  • Ischemic cardiomyopathy
  • Cardiomyopathy due to chronic excess of alcohol consumption (>100 g\day)
  • Congenital heart disease
  • Acquired valvular heart disease
  • Metabolic cardiomyopathy: thyrotoxicosis, hypothyroidism, adrenal cortical insufficiency, pheochromocytoma, acromegaly
  • Familiar storage and infiltrative diseases (hemochromatosis, glycogen storage, Hurler’s syndrome, Niemann-Pick disease; primary, secondary, familial and hereditary cardiac amyloidoses)
  • Systemic diseases (connective tissue disorder; sarcoidosis)
  • Peripartum cardiomyopathy
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Catholic University of the Sacred Heart
Fondazione Telethon
Principal Investigator: Fulvio Bellocci, MD Catholic University of Sacred Heart
Catholic University of the Sacred Heart
May 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP